GP 531

Drug Profile

GP 531

Alternative Names: GP 1531

Latest Information Update: 23 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SICOR
  • Developer PeriCor Therapeutics; SICOR
  • Class Anti-ischaemics; Antithrombotics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Myocardial ischaemia; Unstable angina pectoris

Most Recent Events

  • 22 Jun 2009 Phase II development is ongoing in the US
  • 23 May 1997 A study has been added to the Ischaemic Heart Disease pharmacodynamics section
  • 22 May 1996 Phase-II clinical trials for Myocardial ischaemia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top